Nanofiber-based systems intended for diabetes

Table 1 Various characteristics of nanofibrous delivery systems incorporated with insulin

Type of polymer/material	Diameter of nanofiber (nm)	Applied cell type/animal	Main finding	Refs.
PuraMatrix™	–^a	Male Wistar rats	PGLmarkedly decreased and maintained up to 24 h via subcutaneous route	[37]
PVA-co-PE/CS	100–600	–	Nanofibers with the electrochemically controlled release system	[85]
PLGA/nHA-I	520	Osteoblastic cells (MC3T3-E1)	Accelerate the cell adhesion, proliferation, and differentiation of the osteoblastic cells	[86]
PLGA	432 ± 106	Atrial fibroblasts/prague–Dawley rats	Supported accelerated wound healing and favored epithelial cell proliferation	[87]
FSP	360 ± 37	Caco-2 cells	Physically protect the degradation of insulin and increased transport crossing the cell monolayer	[88]
PVA/NaAlg	300–400	Induced diabetes Wistar rats	The composite nanofibers serve as an ideal carrier for the delivery of insulin via the sublingual route	[89]
CS/PEO	200–2000	3T3-L1 preadipocyte cells/ex-vivo porcine buccal mucosa	Nanofiber mats capable of delivering insulin via the buccal mucosa	[90]

^aNot available data in the article
PuraMatrix™ acetyl-(Arg-Ala-Asp-Ala)₄-CONH₂, PGL plasma glucose level, PVA poly (vinyl alcohol), PE poly(ethylene), CS Chitosan, PLGA/nHA-I poly(lactide-co-glycolide)/insulin-grafted hydroxyapatite nanorods, FSP fish sarcoplasmic protein, NaAlg sodium alginate, PEO poly(ethylene oxide)

ISSN: 1477-3155